Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk ICU admission 40% c19melatonin.com Mousavi et al. Melatonin for COVID-19 RCT LATE TREATMENT Favors melatonin Favors control
Mousavi, 96 patient melatonin late treatment RCT: 67% lower mortality [p=0.62] and 40% lower ICU admission [p=0.41] https://c19p.org/mousavi
copied to clipboard
Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial
Mousavi et al., Journal of Medical Virology, doi:10.1002/jmv.27312
30 Aug 2021    Source   PDF   Share   Tweet
RCT 96 hospitalized patients in Iran, 48 treated with melatonin, showing improved sleep quality and SpO2 with treatment. 3mg oral melatonin daily. Authors recommend studies with a higher dose. IRCT20200411047030N1.
risk of death, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 48 (2.1%), control 3 of 48 (6.2%), NNT 24, day 10.
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.41, treatment 6 of 48 (12.5%), control 10 of 48 (20.8%), NNT 12, day 10.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mousavi et al., 8/30/2021, Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 7 authors.
All Studies   Meta Analysis
This PaperMelatoninAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit